Cytokines as therapeutic targets: advances and limitations.
Biological therapies targeting cytokines, T cells, or B cells have improved outcomes of inflammatory diseases. However, many issues remain open: What is the best target? How well can response be predicted? How can cure be achieved?
Scheinecker
Clemens
C
Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Redlich
Kurt
K
Smolen
Josef S
JS
D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000502:physiology*; D016503:Drug Delivery Systems / Q000009:adverse effects / Q000379:methods* / Q000639:trends*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology*; D016032:Randomized Controlled Trials as Topic
D016207:Cytokines